View Item 

Show simple item record

2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis

dc.contributor.authorKhanna, Dineshen_US
dc.contributor.authorKhanna, Puja P.en_US
dc.contributor.authorFitzgerald, John D.en_US
dc.contributor.authorSingh, Manjit K.en_US
dc.contributor.authorBae, Sangmeeen_US
dc.contributor.authorNeogi, Tuhinaen_US
dc.contributor.authorPillinger, Michael H.en_US
dc.contributor.authorMerill, Joanen_US
dc.contributor.authorLee, Susanen_US
dc.contributor.authorPrakash, Shraddhaen_US
dc.contributor.authorKaldas, Marianen_US
dc.contributor.authorGogia, Maneeshen_US
dc.contributor.authorPerez‐ruiz, Fernandoen_US
dc.contributor.authorTaylor, Willen_US
dc.contributor.authorLioté, Frédéricen_US
dc.contributor.authorChoi, Hyonen_US
dc.contributor.authorSingh, Jasvinder A.en_US
dc.contributor.authorDalbeth, Nicolaen_US
dc.contributor.authorKaplan, Sanforden_US
dc.contributor.authorNiyyar, Vandanaen_US
dc.contributor.authorJones, Danielleen_US
dc.contributor.authorYarows, Steven A.en_US
dc.contributor.authorRoessler, Blakeen_US
dc.contributor.authorKerr, Gailen_US
dc.contributor.authorKing, Charlesen_US
dc.contributor.authorLevy, Geralden_US
dc.contributor.authorFurst, Daniel E.en_US
dc.contributor.authorEdwards, N. Lawrenceen_US
dc.contributor.authorMandell, Brianen_US
dc.contributor.authorSchumacher, H. Ralphen_US
dc.contributor.authorRobbins, Marken_US
dc.contributor.authorWenger, Neilen_US
dc.contributor.authorTerkeltaub, Roberten_US
dc.date.accessioned2012-10-02T17:20:29Z
dc.date.available2013-11-04T19:53:16Zen_US
dc.date.issued2012-10en_US
dc.identifier.citationKhanna, Dinesh; Khanna, Puja P.; Fitzgerald, John D.; Singh, Manjit K.; Bae, Sangmee; Neogi, Tuhina; Pillinger, Michael H.; Merill, Joan; Lee, Susan; Prakash, Shraddha; Kaldas, Marian; Gogia, Maneesh; Perez‐ruiz, Fernando ; Taylor, Will; Lioté, Frédéric ; Choi, Hyon; Singh, Jasvinder A.; Dalbeth, Nicola; Kaplan, Sanford; Niyyar, Vandana; Jones, Danielle; Yarows, Steven A.; Roessler, Blake; Kerr, Gail; King, Charles; Levy, Gerald; Furst, Daniel E.; Edwards, N. Lawrence; Mandell, Brian; Schumacher, H. Ralph; Robbins, Mark; Wenger, Neil; Terkeltaub, Robert (2012). "2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis." Arthritis Care & Research 64(10): 1447-1461. <http://hdl.handle.net/2027.42/93765>en_US
dc.identifier.issn2151-464Xen_US
dc.identifier.issn2151-4658en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/93765
dc.publisherJohn Wiley & Sons, Inc.en_US
dc.title2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arboren_US
dc.contributor.affiliationumIHA University of Michigan Health System, Chelseaen_US
dc.contributor.affiliationotherRochester General Health System, Rochester, New Yorken_US
dc.contributor.affiliationotherVA Medical Center and University of Alabama, Birminghamen_US
dc.contributor.affiliationotherUniversité Paris Diderot, Sorbonne Paris Cité, and Hôpital Lariboisière, Paris, Franceen_US
dc.contributor.affiliationotherUniversity of Otago, Wellington, New Zealanden_US
dc.contributor.affiliationotherHospital Universitario Cruces, Vizcaya, Spainen_US
dc.contributor.affiliationotherVA Healthcare System and University of California, San Diegoen_US
dc.contributor.affiliationotherOklahoma Medical Research Foundation, Oklahoma Cityen_US
dc.contributor.affiliationotherVA Medical Center and New York University School of Medicine, New Yorken_US
dc.contributor.affiliationotherBoston University Medical Center, Boston, Massachusettsen_US
dc.contributor.affiliationotherUniversity of California, Los Angelesen_US
dc.contributor.affiliationotherUniversity of Florida, Gainesvilleen_US
dc.contributor.affiliationotherVA Healthcare System/University of California, San Diego, 111K, 3350 La Jolla Village Drive, San Diego, CA 92161en_US
dc.contributor.affiliationotherHarvard Vanguard Medical Associates/Atrius Health, Somerville, Massachusettsen_US
dc.contributor.affiliationotherCleveland Clinic, Cleveland, Ohioen_US
dc.contributor.affiliationotherVA Medical Center and University of Pennsylvania, Philadelphiaen_US
dc.contributor.affiliationotherSouthern California Permanente Medical Group, Downeyen_US
dc.contributor.affiliationotherNorth Mississippi Medical Center, Tupeloen_US
dc.contributor.affiliationotherVeterans Affairs Medical Center, Washington, DCen_US
dc.contributor.affiliationotherEmory University, Atlanta, Georgiaen_US
dc.contributor.affiliationotherOral and Maxillofacial Surgery, Beverly Hills, Californiaen_US
dc.contributor.affiliationotherUniversity of Auckland, Auckland, New Zealanden_US
dc.identifier.pmid23024029en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/93765/1/21773_ftp.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/93765/2/ACR_21773_sm_SupplFig1.pdf
dc.identifier.doi10.1002/acr.21773en_US
dc.identifier.sourceArthritis Care & Researchen_US
dc.identifier.citedreferenceWillburger RE, Mysler E, Derbot J, Jung T, Thurston H, Kreiss A, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology (Oxford) 2007; 46: 1126 – 32.en_US
dc.identifier.citedreferenceKhanna D, FitzGerald JD, Khanna PP, Bae S, Singh MK, Neogi N, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: 1431 – 46.en_US
dc.identifier.citedreferenceAhern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987; 17: 301 – 4.en_US
dc.identifier.citedreferencePaulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout: a placebo‐controlled study of probenecid‐treated patients. Arthritis Rheum 1974; 17: 609 – 14.en_US
dc.identifier.citedreferenceBrook RA, Forsythe A, Smeeding JE, Lawrence EN. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin 2010; 26: 2813 – 21.en_US
dc.identifier.citedreferenceEdwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ 2011; 14: 10 – 5.en_US
dc.identifier.citedreferenceShoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321 – 5.en_US
dc.identifier.citedreferenceBecker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph‐Ridge N. Determinants of the clinical outcomes of gout during the first year of urate‐lowering therapy. Nucleosides Nucleotides Nucleic Acids 2008; 27: 585 – 91.en_US
dc.identifier.citedreferenceBriesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28: 437 – 43.en_US
dc.identifier.citedreferenceZhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301 – 11.en_US
dc.identifier.citedreferenceZhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312 – 24.en_US
dc.identifier.citedreferenceRomeijnders AC, Gorter KJ. Summary of the Dutch College of General Practitioners' “gout” standard. Ned Tijdschr Geneeskd 2002; 146: 309 – 13. In Dutch.en_US
dc.identifier.citedreferenceJordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46: 1372 – 4.en_US
dc.identifier.citedreferenceZhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011; 63: 3136 – 41.en_US
dc.identifier.citedreferenceIchikawa N, Taniguchi A, Urano W, Nakajima A, Yamanaka H. Comorbidities in patients with gout. Nucleosides Nucleotides Nucleic Acids 2011; 30: 1045 – 50.en_US
dc.identifier.citedreferenceRichette P, Ottaviani S, Bardin T. New therapeutic options for gout. Presse Med 2011; 40: 844 – 9. In French.en_US
dc.identifier.citedreferenceTerkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6: 30 – 8.en_US
dc.identifier.citedreferenceYang LP. Oral colchicine (Colcrys): in the treatment and prophylaxis of gout. Drugs 2010; 70: 1603 – 13.en_US
dc.identifier.citedreferenceBrook R. The RAND/UCLA Appropriateness Method. In: McCormick KA, Moore SR, Siegel RA, editors. Methodology perspectives: AHCPR no. 95‐0009. Rockville (MD): Public Health Service; 1994. p. 59 – 70.en_US
dc.identifier.citedreferenceJones KR, Vojir CP, Hutt E, Fink R. Determining mild, moderate, and severe pain equivalency across pain‐intensity tools in nursing home residents. J Rehabil Res Dev 2007; 44: 305 – 14.en_US
dc.identifier.citedreferenceMendoza TR, Chen C, Brugger A, Hubbard R, Snabes M, Palmer SN, et al. Lessons learned from a multiple‐dose post‐operative analgesic trial. Pain 2004; 109: 103 – 9.en_US
dc.identifier.citedreferenceHunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154 – 235.en_US
dc.identifier.citedreferenceSingh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625 – 39.en_US
dc.identifier.citedreferenceGrossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515 – 26.en_US
dc.identifier.citedreferenceRees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof‐of‐ concept observational study. Ann Rheum Dis 2012. E‐pub ahead of print.en_US
dc.identifier.citedreferenceSchumacher HR Jr, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488 – 92.en_US
dc.identifier.citedreferenceTerkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty‐four–hour outcome of the first multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison colchicine study. Arthritis Rheum 2010; 62: 1060 – 8.en_US
dc.identifier.citedreferenceAlloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20: 111 – 3.en_US
dc.identifier.citedreferenceMan CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double‐blind, randomized, controlled trial. Ann Emerg Med 2007; 49: 670 – 7.en_US
dc.identifier.citedreferenceSwarup A, Sachdeva N, Schumacher HR Jr. Dosing of antirheumatic drugs in renal disease and dialysis. J Clin Rheumatol 2004; 10: 190 – 204.en_US
dc.identifier.citedreferenceTerkeltaub RA, Furst DE, DiGiacinto JL, Kook KA, Davis MW. Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors [published erratum appears in Arthritis Rheum 2011;63:3521]. Arthritis Rheum 2011; 63: 2226 – 37.en_US
dc.identifier.citedreferenceKeenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011; 124: 155 – 63.en_US
dc.identifier.citedreferenceAltman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988; 15: 1422 – 6.en_US
dc.identifier.citedreferenceCattermole GN, Man CY, Cheng CH, Graham CA, Rainer TH. Oral prednisolone is more cost‐effective than oral indomethacin for treating patients with acute gout‐like arthritis. Eur J Emerg Med 2009; 16: 261 – 6.en_US
dc.identifier.citedreferenceMaccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout. Curr Med Res Opin 1991; 12: 423 – 9.en_US
dc.identifier.citedreferenceSturge RA, Scott JT, Hamilton EB, Liyanage SP, Dixon AS, Davies J, et al. Multicentre trial of naproxen and phenylbutazone in acute gout. Ann Rheum Dis 1977; 36: 80 – 2.en_US
dc.identifier.citedreferenceKarachalios GN, Donas G. Sulindac in the treatment of acute gout arthritis. Int J Tissue React 1982; 4: 297 – 9.en_US
dc.identifier.citedreferenceRubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50: 598 – 606.en_US
dc.identifier.citedreferenceSchumacher HR, Berger MF, Li‐Yu J, Perez‐Ruiz F, Burgos‐ Vargas R, Li C. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol 2012. E‐pub ahead of print.en_US
dc.identifier.citedreferenceFDA prescribing information for COLCRYS. 2009. URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022351lbl.pdf.en_US
dc.identifier.citedreferenceWason S, Faulkner RD, Davis MW. Colchicine dosing guidelines for gout patients with varying degrees of renal impairment based on pharmacokinetic data [abstract]. Arthritis Rheum 2011; 63 Suppl: S1013.en_US
dc.identifier.citedreferenceFernandez C, Noguera R, Gonzalez JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide [letter]. J Rheumatol 1999; 26: 2285 – 6.en_US
dc.identifier.citedreferenceJanssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double‐blind, randomised equivalence trial. Lancet 2008; 371: 1854 – 60.en_US
dc.identifier.citedreferenceSo A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL‐1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28.en_US
dc.identifier.citedreferenceChen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010; 40: 210 – 4.en_US
dc.identifier.citedreferenceSchlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health‐related quality of life in patients with difficult‐to‐treat gouty arthritis by suppressing inflammation: results of a randomized, dose‐ranging study. Arthritis Res Ther 2011; 13: R53.en_US
dc.identifier.citedreferenceSo A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: results of a multicenter, phase II, dose‐ranging study. Arthritis Rheum 2010; 62: 3064 – 76.en_US
dc.identifier.citedreferenceGroff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19: 329 – 36.en_US
dc.identifier.citedreferenceJanssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008; 2: CD005521.en_US
dc.identifier.citedreferenceSchlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002; 29: 331 – 4.en_US
dc.identifier.citedreferenceBecker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450 – 61.en_US
dc.identifier.citedreferenceSundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez‐Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306: 711 – 20.en_US
dc.identifier.citedreferenceBecker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12: R63.en_US
dc.identifier.citedreferenceWortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate‐lowering therapy: analysis of data from three phase III trials. Clin Ther 2010; 32: 2386 – 97.en_US
dc.identifier.citedreferenceBorstad GC, Bryant LR, Abel MP, Scroogie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31: 2429 – 32.en_US
dc.identifier.citedreferenceSchumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al. Rilonacept (interleukin‐1 trap) in the prevention of acute gout flares during initiation of urate‐lowering therapy: results of a phase II randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 2012; 64: 876 – 84.en_US
dc.identifier.citedreferenceSchlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double‐blind, randomised study. Ann Rheum Dis 2011; 70: 1264 – 71.en_US
dc.identifier.citedreferenceBrook RA, Kleinman NL, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, et al. The economic burden of gout on an employed population. Curr Med Res Opin 2006; 22: 1381 – 9.en_US
dc.identifier.citedreferenceKleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, et al. The impact of gout on work absence and productivity. Value Health 2007; 10: 231 – 7.en_US
dc.identifier.citedreferenceKhanna P, Khanna D. Health‐related quality of life and outcome measures in gout. In: Terkeltaub R, editor. Gout and other crystal arthropathies. Philadelphia: Elsevier; 2011. p. 217 – 25.en_US
dc.identifier.citedreferenceSaag KG, Olivieri JJ, Patino F, Mikuls TR, Allison JJ, MacLean CH. Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics. Arthritis Rheum 2004; 51: 337 – 49.en_US
dc.identifier.citedreferenceFravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother 2011; 9: 271 – 85.en_US
dc.identifier.citedreferenceRisser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. Am Fam Physician 2009; 80: 1371 – 8.en_US
dc.identifier.citedreferenceMikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, et al. Quality of care indicators for gout management. Arthritis Rheum 2004; 50: 937 – 43.en_US
dc.identifier.citedreferenceSchlesinger N, Moore DF, Sun JD, Schumacher HR Jr. A survey of current evaluation and treatment of gout. J Rheumatol 2006; 33: 2050 – 2.en_US
dc.identifier.citedreferenceGarcia Rodriguez LA, Gonzalez‐Perez A, Bueno H, Hwa J. NSAID use selectively increases the risk of non‐fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One 2011; 6: e16780.en_US
dc.identifier.citedreferenceGrainger R, Taylor WJ, Dalbeth N, Perez‐Ruiz F, Singh JA, Waltrip RW, et al. Progress in measurement instruments for acute and chronic gout studies. J Rheumatol 2009; 36: 2346 – 55.en_US
dc.identifier.citedreferenceGaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum 2012; 64: 1508 – 17.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
21773_ftp.pdf
Size:
741.9KB
Format:
PDF
View/Open
Name:
ACR_21773_sm_SupplFig1.pdf
Size:
53.58KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.